125 related articles for article (PubMed ID: 16867907)
1. Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy.
Ohno T; Sakamoto T; Mizumoto C; Miyoshi T; Ueda M; Takeoka T; Yamashita K; Hishita T; Hada S
Int J Hematol; 2006 Jul; 84(1):74-8. PubMed ID: 16867907
[TBL] [Abstract][Full Text] [Related]
2. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
4. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Dworzak MN; Schumich A; Printz D; Pötschger U; Husak Z; Attarbaschi A; Basso G; Gaipa G; Ratei R; Mann G; Gadner H
Blood; 2008 Nov; 112(10):3982-8. PubMed ID: 18780832
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
[TBL] [Abstract][Full Text] [Related]
6. [Marfan syndrome complicated with CD5+ CD10+ diffuse large B-cell lymphoma].
Yoshitake K; Hagiwara Y; Tanae K; Takahashi N; Kohri M; Tamaru J; Bessho M; Niitsu N
Rinsho Ketsueki; 2010 Mar; 51(3):196-200. PubMed ID: 20379114
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
[TBL] [Abstract][Full Text] [Related]
8. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
Pels H; Schulz H; Schlegel U; Engert A
Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
[TBL] [Abstract][Full Text] [Related]
9. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.
Chu PG; Chen YY; Molina A; Arber DA; Weiss LM
Leuk Lymphoma; 2002 Dec; 43(12):2335-41. PubMed ID: 12613521
[TBL] [Abstract][Full Text] [Related]
10. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
[TBL] [Abstract][Full Text] [Related]
11. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.
Harjunpää A; Wiklund T; Collan J; Janes R; Rosenberg J; Lee D; Grillo-López A; Meri S
Leuk Lymphoma; 2001 Aug; 42(4):731-8. PubMed ID: 11697503
[TBL] [Abstract][Full Text] [Related]
12. In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia.
Berkahn L; Simpson D; Raptis A; Klingemann HG
J Hematother Stem Cell Res; 2002 Apr; 11(2):315-20. PubMed ID: 11983102
[TBL] [Abstract][Full Text] [Related]
13. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
14. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
[TBL] [Abstract][Full Text] [Related]
16. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
Yokose N; Shioi Y; Sugisaki Y; Ohaki Y; Ogata K; Dan K
Leuk Lymphoma; 2006 Jul; 47(7):1415-7. PubMed ID: 16923582
[No Abstract] [Full Text] [Related]
17. Effective in vivo purging with rituximab and autologous peripheral blood stem cell transplantation in a woman with CD5 positive primary cutaneous diffuse large B-cell lymphoma.
Goto H; Nishio M; Endo T; Sato N; Koizumi K; Fujimoto K; Sakai T; Kumano K; Obara M; Koike T
Eur J Haematol; 2005 Jun; 74(6):526-8. PubMed ID: 15876258
[TBL] [Abstract][Full Text] [Related]
18. Intravascular large B-cell lymphoma as a cause of hypopituitarism: gradual and late reversal of hypopituitarism after long-term remission of lymphoma with immunochemotherapy.
Pekic S; Milicevic S; Colovic N; Colovic M; Popovic V
Endocrine; 2008; 34(1-3):11-6. PubMed ID: 18937075
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.
van der Kolk LE; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2003 Aug; 17(8):1658-64. PubMed ID: 12886256
[TBL] [Abstract][Full Text] [Related]
20. Large B-cell lymphoma manifesting as an invasive cardiac mass: sustained local remission after combination of methotrexate and rituximab.
Cohen Y; Daas N; Libster D; Gillonb D; Polliack A
Leuk Lymphoma; 2002 Jul; 43(7):1485-7. PubMed ID: 12389634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
